|
Fig. 2. Whole-mount in situ hybridization using XFD-11 antisense RNA. (A) stage 10.5 (veg.-dors.), (B) stage 12.5 (veg.-dors.), (C) stage 16 (post.), (D) stage 20 (ant.). E: Lateral view, anterior to the right. (E) stage 25/26, (F) stage 28/29, (G) stage 29 (cleared in benzyl benzoate), (H) stage 32, (I) stage 36, (J) stage 35 (cleared in benzyl benzoate). K: 50-mm transverse sections at the posterior region (K, L), at the trunk region (N, O, P), at the head region (Q, R) and horizontal section at the lower head region (S). (K) stage 15, (L) stage 15 (higher magnification), (M) stage 29, (N) stage 26, (O) stage 28, (P) stage 35/ 36, (Q) stage 30, (R) stage 30 (higher magnification). (S) stage 35/36. a, archenteron; ae, anterior eye ridge; an, anterior neural plate; cg, cement gland; dl, dorsal blastopore lip; dm, dorsal midline; e, eye; en, endoderm; g, gut; h, heart; hm, head mesenchyme; lbn, lateral border of neural plate; lm, lateral mesoderm; m, mesencephalon; n, notochord; nc, neural crest cells; np, neural plate; pm, posterior mesoderm; pn, pronephros; pnt, pronephric tubule; sc, spinal cord; som, somatic layer of lateral plate mesoderm; spm, splanchnic layer of lateral plate mesoderm; t, tip of tail. |